mRNA-1273 is placenta-permeable and immunogenic in the fetus [PDF]
Molecular Therapy: Nucleic AcidsCOVID-19 mRNA vaccines are generally recognized as safe for gestational administration. However, their transplacental pharmacokinetics remain obscure. In this study, mRNA-1273 intramuscularly given to pregnant mice rapidly circulated in maternal blood ...
Jeng-Chang Chen +7 more
doaj +3 more sources
Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents [PDF]
Human Vaccines & ImmunotherapeuticsSafety, immunogenicity, and effectiveness of an mRNA-1273 50-μg booster were evaluated in adolescents (12–17 years), with and without pre-booster SARS-CoV-2 infection.
Amparo L. Figueroa +10 more
doaj +3 more sources
Profiling antibody epitopes induced by mRNA-1273 vaccination and boosters [PDF]
Frontiers in ImmunologyBackgroundCharacterizing the antibody epitope profiles of messenger RNA (mRNA)-based vaccines against SARS-CoV-2 can aid in elucidating the mechanisms underlying the antibody-mediated immune responses elicited by these vaccines.MethodsThis study ...
Bethany Girard +17 more
doaj +4 more sources
Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases [PDF]
Nature CommunicationsPrimary vaccination with mRNA-1273 (100-µg) was safe and efficacious at preventing coronavirus disease 2019 (COVID-19) in the previously reported, blinded Part A of the phase 3 Coronavirus Efficacy (COVE; NCT04470427) trial in adults (≥18 years) across ...
Lindsey R. Baden +24 more
doaj +3 more sources
Safety of COVID-19 mRNA-1273 booster doses in Asian populations: A literature review of post-marketing observational studies [PDF]
Human Vaccines & ImmunotherapeuticsReal-world data on the safety of COVID-19 booster doses in Asian populations are needed to inform national immunization programs. The safety profile of mRNA-1273 (Moderna, Inc.) was evaluated using post-marketing observational data.
Chris Clarke +4 more
doaj +2 more sources
Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age [PDF]
VaccinesBackground/Objectives: Streptococcus pneumoniae with, or following, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been associated with increased mortality, particularly in older adults.
Tosin Omole +12 more
doaj +2 more sources
Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE [PDF]
Infectious Diseases and TherapyIntroduction Immunocompromised (IC) patients mount poor immune responses to vaccination. Higher-dose coronavirus disease 2019 (COVID-19) vaccines may offer increased immunogenicity.
Sushma Kavikondala +11 more
doaj +2 more sources
Clinical Course, Outcomes, and Risk Factors of Myocarditis and Pericarditis Following Administration of mRNA-1273 Vaccination: A Protocol for a Federated Real-World Evidence Vaccine Safety Study Using Data from Five European Data Sources [PDF]
VaccinesBackground: Myocarditis and pericarditis are recognised risks following COVID-19 vaccination, including the mRNA-1273 vaccine. Most cases occur shortly following the second dose of this vaccine, and incidence is highest among young males. However, little
Laura C. Zwiers +23 more
doaj +2 more sources
International Journal of Infectious Diseases, 2022 Objectives: There are limited comparative immunologic durability data post COVID-19 vaccinations. Methods: Approximately 8.4 months after primary COVID-19 vaccination, 647 healthcare workers completed surveys about COVID-19 vaccinations/infections and ...
Wendy M. Brunner +13 more
doaj +1 more source